Analysis of Patients With Stage IIIC Endometrial Cancer

Turan, Taner; Üreyen, Işın; Duzguner, Ipek Nur Balin; Özkaya, Enis; Taşçı, Tolga; Karalök, Alper; Boran, Nurettin; Köse, Mehmet; Tulunay, Gökhan

doi:10.1097/igc.0000000000000154

Cited by 15 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LNM is one of the most important prognostic factors for EC; therefore, the prediction of LNM preoperatively has a critical significance in the treatment plan [12]. Preoperative CA125 level is useful as a reliable tumor marker in the management of EC [3,6,13,14].…”

Section: Discussionmentioning

confidence: 99%

The preoperative serum CA125 can predict the lymph node metastasis in endometrioid-type endometrial cancer

et al. 2018

Self Cite

View full text Add to dashboard Cite

Objectives: To evaluate the predictive value of preoperative CA125 in extra-uterine disease and its association with poor prognostic factors in endometrioid-type endometrial cancer (EC). Material and methods: A total of 423 patients with pathologically proven endometrioid-type EC were included in the study. The association between preoperative CA125 level and surgical-pathological factors was evaluated. The conventional cutoff value was defined as 35 IU/mL. Results: A high CA125 level (> 35 IU/mL) was significantly associated with all of the studied poor prognostic factors, except grade. The risk of lymph node metastasis (LNM) increased from 15.9% to 45.7% when CA125 level was > 35 IU/mL (p < 0.05). The optimal cutoff value for the prediction of LNM in patients aged > 50 years was determined to be 16 IU/mL (sensitivity, specificity, positive predictive value, and negative predictive value were 71%, 60%, 35%, and 87%, respectively.) Conclusions: Preoperative CA125 level was significantly related with the extent of the disease and LNM. The age-dependent cutoff level of CA125 can improve the prediction of LNM in endometrioid-type EC. For older patients, CA125 level of > 16 IU/ml could be used to predict LNM. However, further studies are needed to evaluate the appropriate cutoff level of CA125 for younger patients.

show abstract

Section: Discussionmentioning

confidence: 99%

The preoperative serum CA125 can predict the lymph node metastasis in endometrioid-type endometrial cancer

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Additionally, 77% of metastatic lymph nodes in the paraaortic region were located between the inferior mesenteric artery and the renal vein [16]. Turan et al [17] also reported similar rates of metastatic lymph node locations as 38% only pelvic, 45% pelvic and paraaortic, and 16% only paraaortic in their study. Odagiri et al [18] evaluated the recurrence pattern and survival of 147 patients with stage IIIC1 to IIIC2 endometrial carcinoma, and they concluded that recurrence is the only independent prognostic factor for survival and the number of harvested lymph nodes along with paraaortic lymph node metastasis predicted the recurrence risk.…”

Section: Discussionmentioning

confidence: 55%

Effect of Lymphadenectomy on Survival in Early-Stage Type II Endometrial Carcinoma and Carcinosarcoma

Vatansever

Sözen

Ersoy

et al. 2020

Journal of Oncology

View full text Add to dashboard Cite

Purpose. We aimed to investigate whether systematic pelvic and paraaortic lymph node dissection delivers any survival advantage in a subgroup of patients with type II endometrial carcinoma and carcinosarcoma. Methods. We evaluated 135 patients with clinically early-stage (Stage I-II) type II endometrial carcinoma and carcinosarcoma who underwent systematic pelvic and paraaortic lymph node dissection or who did not undergo any lymph node dissection. Results. Overall survival (OS) and recurrence-free survivals (RFS) were significantly longer in the systematic lymph node dissection group (hazard ratio 0.28, 95% CI 0.13–0.62 p=0.002 for OS and hazard ratio 0.31, 95% CI 0.14–0.69 p=0.004 for RFS). Multivariate analysis showed that lymph node dissection, age, lymph node metastasis, and adjuvant therapy were independent prognostic variables of OS and RFS. Conclusions. Systematic pelvic and paraaortic lymph node dissection independently and significantly prolongs the survival of patients with early-stage type II endometrial carcinoma and carcinosarcoma.

show abstract

“…Recurrence rate varying according to clinical factors, stage and pathologic findings; is approximately 11-13% within 2 years after initial treatment in EC patients (3)(4)(5). Extra-pelvic disease was present in 70% of recurrent patients' diagnosed high grade EC (6)(7)(8)(9)(10).…”

Section: Introductionmentioning

confidence: 99%

Recurrence Pattern after Adjuvant Radiotherapy for Endometrioid Type Endometrial Cancer

Durmuş

Türkmen

Kılıç

et al. 2018

Gynecol Obstet Reprod Med

Self Cite

View full text Add to dashboard Cite

Objective: To define recurrence pattern of endometrioid type endometrium cancer performed adjuvant radiotherapy.Study Design: 351 patients who underwent at least total abdominal hysterectomy with bilateral salpingo-oophorectomy and followed by adjuvant radiotherapy (vaginal brachytherapy or pelvic radiotherapy or both) for endometrioid type endometrium carcinoma were included. The patients who received systemic adjuvant treatment after surgery were excluded from the study except for 18 patients who received concomitant chemo-radiotherapy. Recurrence was categorized as pelvic recurrence included areas distal to the pelvic inlet, as abdominal recurrence included areas between pelvic inlet and diaphragm and findings such as ascites and peritonitis carcinomatosa, and the rest of recurrences including lung, cutaneous, liver parenchyma and bone as extra-abdominal recurrence.Results: The median age was 57 years (range; 29-82). 236 patients had stage I, 25 had stage II, 63 had stage III and 14 had stage IV disease (by FIGO 2009). Lymph node metastasis was determined in 21.8% of patients who underwent lymphadenectomy (n: 289). The median follow-up time was 46 months (range; 1-190). Throughout follow-up, recurrence was developed in 55 (15.7%) patients. Only pelvic recurrence was determined in 11 (3.1%) patients. There was recurrence beyond the pelvis in 44 (80%) of the recurrent patients. Thirty-five (%63.6) of recurrent patients had extra-abdominal recurrence. Twenty-three (41.8%) of recurrent patients had stage IB disease. The recurrence developed in 10% of patients with stage I&II, whereas it was occurred in 31% of patients with stage III&IV (p<0.0001).Conclusion: Radiotherapy provides local control of the disease, but recurrence is likely to be extra-pelvic and extra-abdominal in this patient group.

show abstract

Analysis of Patients With Stage IIIC Endometrial Cancer

Cited by 15 publications

References 26 publications

The preoperative serum CA125 can predict the lymph node metastasis in endometrioid-type endometrial cancer

The preoperative serum CA125 can predict the lymph node metastasis in endometrioid-type endometrial cancer

Effect of Lymphadenectomy on Survival in Early-Stage Type II Endometrial Carcinoma and Carcinosarcoma

Recurrence Pattern after Adjuvant Radiotherapy for Endometrioid Type Endometrial Cancer

Contact Info

Product

Resources

About